期刊文献+

敷胸巴布剂与敷胸散治疗小儿肺炎的临床疗效比较研究 被引量:12

Comparative Study of Clinical Efficacy between Fuxiong Cataplasms and Fuxiong Powder in Children Pneumonia
下载PDF
导出
摘要 目的:观察敷胸巴布剂与传统敷胸散治疗小儿肺炎的临床疗效。方法:采用随机、对照的方法,将50例小儿肺炎患儿,分为治疗组和对照组各25例,对照组采用基础治疗加敷胸散外治疗法;治疗组采用基础治疗加敷胸巴布剂外治疗法。观察两组临床疗效、肺部体征改善情况。结果:治疗组和对照组在疾病总疗效和皮肤刺激方面无显著性差异(P>0.05);治疗组在改善患儿咳嗽,咯痰症状,缩短肺部罗音的吸收方面,明显优于对照组(P<0.05)。结论:敷胸巴布剂在提高小儿肺炎临床疗效方面优于敷胸散。 Objective: To observe the clinical curative effect of Fuxiong Cataplasms and Fuxiong Powder for the treatment of children pneumonia.Methods: Using randomized and controlled method,50 cases of children with pneumonia were divided into treatment group and control group( n = 25).The control group used the foundation treatment with Fuxiong Powder therapy and the treatment group the foundation treatment with Fuxiong Cataplasms therapy.We observed the two groups' clinical curative effect and improvement of lung.Results: The total curative effect and skin irritation in treatment group and control group had no significant difference( P〈0.05).Treatment group can improve the cough and sputum plugging and shorten the absorption of lung rale,which was superior to the control group( P〈0.05).Conclusion:Fuxiong Cataplasms was superior to Fuxiong Powder in improving the clinical curative effect of children pneumonia.
出处 《中华中医药学刊》 CAS 北大核心 2016年第4期820-822,共3页 Chinese Archives of Traditional Chinese Medicine
基金 国家自然科学基金项目(81273800)
关键词 敷胸散 巴布剂 肺炎 外治法 Fuxiong Powder cataplasms pneumonia external treatment
  • 相关文献

参考文献4

  • 1Bulletin of the World Health Organization.Diagnostic Criteria for Pneumonia[S].2008,86(5):408-416.
  • 2中华儿科学会呼吸病学组.肺炎诊断标准[S].中医儿科杂志,2001,45(2):83.
  • 3国家中医药管理局.中华人民共和国中医药行业标准-中医病症诊断疗效标准[S].南京:南京大学出版社,1994:201-202.
  • 4祁荣,贺锐锐,李博彧,梁秉文.经皮给药系统研究新进展[J].中医外治杂志,2007,16(1):3-6. 被引量:50

二级参考文献23

  • 1边佳明,曾明,许景峰.微针在经皮给药领域的研究进展[J].中国药学杂志,2006,41(16):1209-1211. 被引量:10
  • 2Morimoto,Kazwnor.Transdermal preparations containing dihydroetorphine[J].CA,1992,129:180,181.
  • 3Chol H K.Composition for transdremal delivery system containing nonsteroidal anti-inflammatory drug as an active ingredient[P].Eur.Pat.Appl.EP 0827741 A2,1998.
  • 4Laneri S,Sacchi A,Di Frasselo E A,et al.Ionized pro drugs of dehydroepiandrosteone for transdermal ion-tophoretic delivery[J].Pharm Res,1999,16 (2):1818 -1824.
  • 5Guy R H,Kalia Y N,Delgado-charro M B,et al.Ion-tophoresis:electrorepulsion and electroosmosis[J].J Controlled Release,2000,64(1-3):29-132.
  • 6Manabe E,Numajiri S,Sugibayashi K,et al.Analysis ofskin permeation-enhancing mechanism of iontophoresisusing hydrodynamic pore theory[J].J Controlled Release,2000,66(3 -3):149 -158.
  • 7Mitragorri S,Blankschtein D,Langer R.Transdermal drug delivery using low -frequency sonophoresis[J].Pharm Res,1996,13(3):411 -420.
  • 8Murthy S N.Magnetophoresis:an approach to enhancetransdermal drug diffusion[J].Pharmazie,1999,54 (5):377 -379.
  • 9US 专利 4,747,841.
  • 10Martanto W,Davis S,Holiday N,et al.Transdermal delivery of insulin using microneedles in vivo[J].Pharm Res,2004,21 (6):947 -952.

共引文献59

同被引文献196

引证文献12

二级引证文献82

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部